Literature DB >> 34125307

DNA Repair Mechanisms and Therapeutic Targets in Glioma.

Kevin B Elmore1, Lauren R Schaff2.   

Abstract

PURPOSE OF REVIEW: This review discusses current and investigative strategies for targeting DNA repair in the management of glioma. RECENT
FINDINGS: Recent strategies in glioma treatment rely on the production of overwhelming DNA damage and inhibition of repair mechanisms, resulting in lethal cytotoxicity. Many strategies are effective in preclinical glioma models while clinical feasibility remains under investigation. The presence of glioma biomarkers, including IDH mutation and/or MGMT promoter methylation, may confer particular susceptibility to DNA damage and inhibition of repair. These biomarkers have been adopted as eligibility criteria in the design of multiple ongoing clinical trials. Targeting DNA repair mechanisms with novel agents or therapeutic combinations is a promising approach to the treatment of glioma. Further investigations are underway to optimize this approach in the clinical setting.

Entities:  

Keywords:  ATM inhibitor; DNA damage response; DNA repair; Glioblastoma; Glioma; PARP inhibitor

Mesh:

Substances:

Year:  2021        PMID: 34125307     DOI: 10.1007/s11912-021-01077-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  69 in total

Review 1.  Genome maintenance mechanisms for preventing cancer.

Authors:  J H Hoeijmakers
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.

Authors:  Ian Hickson; Yan Zhao; Caroline J Richardson; Sharon J Green; Niall M B Martin; Alisdair I Orr; Philip M Reaper; Stephen P Jackson; Nicola J Curtin; Graeme C M Smith
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

3.  ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.

Authors:  Laura Biddlestone-Thorpe; Muhammad Sajjad; Elizabeth Rosenberg; Jason M Beckta; Nicholas C K Valerie; Mary Tokarz; Bret R Adams; Alison F Wagner; Ashraf Khalil; Donna Gilfor; Sarah E Golding; Sumitra Deb; David G Temesi; Alan Lau; Mark J O'Connor; Kevin S Choe; Luis F Parada; Sang Kyun Lim; Nitai D Mukhopadhyay; Kristoffer Valerie
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

4.  Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.

Authors:  Christopher B Jackson; Seth I Noorbakhsh; Ranjini K Sundaram; Aravind N Kalathil; Sachita Ganesa; Lanqi Jia; Hank Breslin; Danielle M Burgenske; Oren Gilad; Jann N Sarkaria; Ranjit S Bindra
Journal:  Cancer Res       Date:  2019-07-04       Impact factor: 12.701

5.  Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.

Authors:  Frank T Zenke; Astrid Zimmermann; Christian Sirrenberg; Heike Dahmen; Vladimir Kirkin; Ulrich Pehl; Thomas Grombacher; Claudia Wilm; Thomas Fuchss; Christiane Amendt; Lyubomir T Vassilev; Andree Blaukat
Journal:  Mol Cancer Ther       Date:  2020-03-27       Impact factor: 6.261

6.  ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration.

Authors:  Guido Fròsina; Aldo Profumo; Daniela Marubbi; Diana Marcello; Jean Louis Ravetti; Antonio Daga
Journal:  Radiat Oncol       Date:  2018-04-23       Impact factor: 3.481

7.  Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.

Authors:  Jian-Fang Ning; Monica Stanciu; Melissa R Humphrey; Joshua Gorham; Hiroko Wakimoto; Reiko Nishihara; Jacqueline Lees; Lee Zou; Robert L Martuza; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  Nat Commun       Date:  2019-07-02       Impact factor: 14.919

8.  Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.

Authors:  E Fokas; R Prevo; J R Pollard; P M Reaper; P A Charlton; B Cornelissen; K A Vallis; E M Hammond; M M Olcina; W Gillies McKenna; R J Muschel; T B Brunner
Journal:  Cell Death Dis       Date:  2012-12-06       Impact factor: 8.469

9.  The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.

Authors:  Stephen T Durant; Li Zheng; Yingchun Wang; Kan Chen; Lingli Zhang; Tianwei Zhang; Zhenfan Yang; Lucy Riches; Antonio G Trinidad; Jacqueline H L Fok; Tom Hunt; Kurt G Pike; Joanne Wilson; Aaron Smith; Nicola Colclough; Venkatesh Pilla Reddy; Andrew Sykes; Annika Janefeldt; Peter Johnström; Katarina Varnäs; Akihiro Takano; Stephanie Ling; Jonathan Orme; Jonathan Stott; Caroline Roberts; Ian Barrett; Gemma Jones; Martine Roudier; Andrew Pierce; Jasmine Allen; Jenna Kahn; Amrita Sule; Jeremy Karlin; Anna Cronin; Melissa Chapman; Kristoffer Valerie; Ruth Illingworth; Martin Pass
Journal:  Sci Adv       Date:  2018-06-20       Impact factor: 14.136

10.  Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like Cells.

Authors:  Shafiq U Ahmed; Ross Carruthers; Lesley Gilmour; Salih Yildirim; Colin Watts; Anthony J Chalmers
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

View more
  4 in total

1.  A novel DNA damage and repair-related gene signature to improve predictive capacity of overall survival for patients with gliomas.

Authors:  Xiaodong Li; Yichang Wang; Wei Wu; Jianyang Xiang; Maode Wang; Hai Yu
Journal:  J Cell Mol Med       Date:  2022-05-26       Impact factor: 5.295

Review 2.  Targeting Cell Cycle Checkpoint Kinases to Overcome Intrinsic Radioresistance in Brain Tumor Cells.

Authors:  Tijana Vlatkovic; Marlon R Veldwijk; Frank A Giordano; Carsten Herskind
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

Review 3.  CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers.

Authors:  Xixi Wu; Junying Wu; Lingxia Wang; Wei Yang; Bo Wang; Huan Yang
Journal:  Front Oncol       Date:  2022-03-16       Impact factor: 6.244

4.  Chronically Radiation-Exposed Survivor Glioblastoma Cells Display Poor Response to Chk1 Inhibition under Hypoxia.

Authors:  Nareg Pinarbasi-Degirmenci; Ilknur Sur-Erdem; Vuslat Akcay; Yasemin Bolukbasi; Ugur Selek; Ihsan Solaroglu; Tugba Bagci-Onder
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.